Involvement of Immune Cell Network in Aortic Valve Stenosis: Communication between Valvular Interstitial Cells and Immune Cells

Seung Hyun Lee and Jae-Hoon Choi*
Department of Life Science, College of Natural Sciences, Research Institute of Natural Sciences, Hanyang University, Seoul 04763, Korea

Aortic valve stenosis is a heart disease prevalent in the elderly characterized by valvular calcification, fibrosis, and inflammation, but its exact pathogenesis remains unclear. Previously, aortic valve stenosis was thought to be caused by chronic passive and degenerative changes associated with aging. However, recent studies have demonstrated that atherosclerotic processes and inflammation can induce valvular calcification and bone deposition, leading to valvular stenosis. In particular, the most abundant cell type in cardiac valves, valvular interstitial cells, can differentiate into myofibroblasts and osteoblast-like cells, leading to valvular calcification and stenosis. Differentiation of valvular interstitial cells can be trigged by inflammatory stimuli from several immune cell types, including macrophages, dendritic cells, T cells, B cells, and mast cells. This review indicates that crosstalk between immune cells and valvular interstitial cells plays an important role in the development of aortic valve stenosis.

[Immune Network 2016;16(1):26-32]

Keywords: Valve, Stenosis, VIC, VEC, Immune cells

INTRODUCTION

Aortic valve stenosis is a degenerative valvular heart disease characterized by narrowing of the aortic valve orifice by severe calcification, fibrosis, and lipid deposition, leading to valve sclerosis. Narrowing of the orifice increases the pressure burden on the left ventricle (1,2). This is a common disease in the elderly, with approximately 21 to 26% of people over 65 years of age with degenerative valve disease, and around 2.8% of those over 75 years of age showing aortic valve stenosis (3,4). The most adverse aspect of aortic valve stenosis is the low survival rate with which it is associated. Without aortic valve replacement, patients with severe aortic stenosis demonstrate poor prognoses. For instance, following detection of symptoms, two- and five-year survival rates of 50 and 25%, respectively, have been reported (5). Another important factor is the limited number of therapy options currently available for aortic valve stenosis patients. Some trials have indicated that statins are effective in slowing the progression of this disease (6,7), but more recently, larger randomized trials have reported negative statin therapy results (8,9). It is thought that inflammation initiates degenerative valve disease and valvular calcification (10,11).
Therefore, to develop a novel therapeutic drug, it is important to understand which immune cells are involved in aortic valve stenosis. In this review, we focus on immune and non-immune cells of the aortic valve and their functions in the progression of this condition.

**VALVULAR INTERSTITIAL CELLS (VICs)**

VICs, the most numerous cell type in cardiac valve, are located under the valvular endothelium, and together with valvular endothelial cells (VECs) are important in maintaining cardiac valve tissue homeostasis (12,13). VICs are highly involved in the progression of aortic valve stenosis, being capable of differentiating into myofibroblasts and osteoblast-like cells, which cause fibrosis and valve calcification, respectively (14,15). Such differentiation is dependent on TGF-β (16-18). In aortic valve stenosis, myofibroblasts produce extracellular collagen and tenasin-C, causing changes to components of the extracellular matrix and tissue fibrosis (19). Osteoblast-like VICs induce calcification through a mechanism similar to osteogenesis (20). These cells produce bone morphogenetic protein 2 and osteopontin, which are important for bone formation (21), and express runt-related transcription factor 2 and osterix—transcription factors involved in osteoblast differentiation (22). VICs can also take up lipids, but not to the same extent as macrophages (23). A recent study by Syvaranta and colleagues showed that, in the stenotic state, myofibroblasts upregulate the scavenger receptors CD36 and lectin-like oxidized low density lipoprotein receptor-1, which are able to bind to oxidized low-density lipoprotein (LDL). In response to oxidized LDL, myofibroblasts produce inflammatory cytokines and chemokines, including MCP-1, IL-6, IL-8, and M-CSF (24). These findings indicate that VIC-derived myofibroblasts are able to take up lipids, and that lipid accumulation is associated with pro-inflammatory processes in aortic valve stenosis. In 2008, Meng and colleagues showed that VICs express TLR2 and TLR4. Treatment with agonists of these TLRs induces NF-κB activation and upregulation of ICAM-1, bone morphogenetic protein 2, and runt-related transcription factor 2 in VICs (25). TLR2- and TLR4-stimulation in these cells also promotes alkaline phosphatase activity and increases calcified nodule formation (26). These findings indicate that the TLR-activated pro-inflammatory process in VICs closely correlates with valvar calcification. In conclusion, VICs participate in various processes, including calcification, fibrosis, lipid uptake, and inflammation in aortic valve stenosis.

**VALVULAR ENDOTHELIAL CELLS (VECs)**

In the normal state, VECs and VICs are important for the maintenance of homeostasis in the cardiac valve (12,13). VECs can differentiate into VICs through endothelial-mesenchymal transition to preserve valve homeostasis (27). Mechanical shearing force or other types of stress can reduce the integrity of valvar endothelium, leading to accumulation of lipoproteins in the subendothelial space. The accumulated LDL molecules are modified into oxidized LDL, and trigger inflammation of cardiac valves by upregulating cell adhesion molecules, such as ICAM-1 and VCAM-1, which allow T cells and monocyte-derived macrophages to infiltrate the tissue (28-31). These infiltrating T cells and macrophages release pro-inflammatory cytokines, including IL-1β and TNF-α (1,32,33). Inflammatory cytokines such as IL-6 and TNF-α induce the differentiation of VECs to VICs via endothelial-mesenchymal transition (34). These observations indicate that VECs play important roles in the initiation and progression of aortic valve disease. Interestingly, in hypercholesterolemia, the peroxisome proliferator-activated receptor gamma (PPARγ) pathway is activated, and related genes, including ATP-binding cassette subfamily A member 1 and fatty acid-binding protein 1, are upregulated in the aortic valve endothelium (35). PPARγ activation in endothelial cells is known to inhibit inflammation of the endothelium (36,37). Therefore, PPARγ may constitute a drug target in valvar endothelium for the treatment of aortic valve stenosis.

**MACROPHAGES**

In cardiac valve disease, monocytes infiltrate valve tissues and differentiate into macrophages (38,39). Macrophages are the principal immune cell population in various valvular heart diseases. Endothelial damage to cardiac valves is known to upregulate endothelial cell adhesion molecules such as ICAM-1 and VCAM-1 that subsequently induce the recruitment of monocytes and other leukocytes (31,38). In addition, a gene expression profiling study by Bosse and colleagues showed that various chemokines and chemokine receptors are upregulated in aortic valve stenosis (40). This indicates that chemotaxis is also involved in the patho-
The Function of Immune Cells in Aortic Valve Stenosis
Seung Hyun Lee and Jae-Hoon Choi

IMMUNE NETWORK Vol. 16, No. 1: 26-32, February, 2016

Figure 1. Presence of dendritic cells (DCs) in mouse cardiac valve. Mitral valve from a CD11c-EYFP transgenic mouse was whole-mount immunostained with MHCII antibody. The CD11c\(^+\) MHCII\(^+\) DCs were then visualized (green, CD11c; red, MHCII). CD11c\(^-\) MHCII\(^+\) DCs are also present in other cardiac valves (aortic, tricuspid, and pulmonary; data not shown). Scale bars, 20 μm.

genes of this disease. After having infiltrated the tissue, macrophages release inflammatory cytokines such as TNF-\(\alpha\), IL-1\(\beta\), and TGF-\(\beta\) leading to cardiac valve inflammation. Moreover, TNF-\(\alpha\) and TGF-\(\beta\) promote VIC activation and induce alkaline phosphatase expression, eventually leading to valvular calcification (16,32,41-43). Macrophages also release matrix metalloproteinases and cathepsins, which alter extracellular matrix components in valvular disease (38). Inflammatory macrophages promote VEC and VIC calcification in a cathepsin S-dependent manner in calcific aortic valve disease and aortic valve stenosis (44). In atherosclerosis, the uptake of LDLs by macrophages results in their becoming foam cells (45,46). Likewise, in hypercholesterolemia-induced valvular sclerosis, recruited macrophages engulf lipids and develop a foamy appearance (23). This suggests that macrophages play important roles in valvular disease, as well as in atherosclerosis. However, further studies are required for a more detailed understanding of macrophage functions and to validate them as therapeutic targets in aortic valve stenosis.

DENDRITIC CELLS (DCs)

DCs, present in normal cardiac valves (Fig. 1), are another important immune cell type. In the aortic valve, DCs are particularly located beneath the aortic-side endothelium, a site exposed to turbulent flow (47). In a normal state, these cells are thought to be classical DCs; however, their role in cardiac valves remains unknown. Considering the atheroprotective role of FLT3-dependent DCs (48), valvular DCs may play regulatory functions in aortic valve stenosis, but additional investigation is needed. In hyperlipidemia, lipids accumulate in the aortic side of the aortic valve, where the majority of valvular DCs are located (47). It has been confirmed that a large number of monocyte-derived DCs amass during atherosclerosis (49), and these same cells have been proposed to accumulate in sclerotic cardiac valves, potentially playing a significant role in aortic valve stenosis progression. However, the relationship between lipid accumulation and DCs and their roles in aortic valve stenosis remains to be elucidated.

T CELLS

T cells also play a role in cardiac valve disease, gathering in valvular tissue during the progression of conditions such as aortic valve stenosis (50). Infiltrating T cells secrete various pro-inflammatory cytokines, including TNF-\(\alpha\), IL-1\(\beta\), and TGF-\(\beta\) (1,33). In a previous study, multiple oligoclonal CD4\(^+\) and CD8\(^+\) T cells were observed to accumulate in stenotic aortic valves, suggesting that clonally expanded T cells are highly involved in the pathogenesis of aortic valve stenosis (51). Moreover, the number of T cells, especially of the CD8\(^+\) and CD8\(^+\)CD28\(^{null}\) memory-effector subsets, is increased in the stenotic aortic valve and peripheral blood of calcific aortic valve stenosis patients (52). T cell proliferation may occur not only in the lymphoid organs but also in the stenotic aortic valve itself, although more investigations are needed. To conclude, the T cell-mediated adaptive immune system is involved in aortic valve stenosis. Considering their abundance, valvular DCs, powerful antigen-presenting cells that can actively interact with T cells (47), may have an important role in regulating valvular T cell activation and proliferation.
**B CELLS**

In the normal state, B cells are not present in cardiac valves, while in the stenotic aortic valve tissue, CD20⁺ B cells and CD138⁺ plasma cells accumulate (50). A recent study by Natorska and colleagues showed that B cells infiltrate the aortic side of human stenotic aortic valve (53). It has been demonstrated that B cells can be activated by TLR signaling (54) or macrophage-secreted cytokines, such as B cell-activating factor belonging to the TNF family (BAFF). The binding of BAFF to its receptor on B cells results in signaling that promotes their survival, maturation, and proliferation (55-57). Importantly, B cells in the stenotic valve also express BAFF receptors, and a positive correlation is evident between the number of these cells and the degree of valve calcification. In addition, correlations exist between the number of B cells and macrophages, and between the number of BAFF receptor-positive B cells and macrophages (53). These findings indicate that, in collaboration with macrophages, B cells also contribute to the progression of aortic valve stenosis via BAFF/BAFF receptor signaling. Monocyte-derived DCs are also known to secrete BAFF (55,58). Therefore, it is plausible that these cells may play a role in B cell activation in aortic valve stenosis.

**MAST CELLS**

Mast cells also participate in the progression of aortic valve stenosis. Under normal conditions, a small number of mast cells are located in the aortic valve. However, their numbers are markedly increased in the subendothelial space of the aortic side of stenotic valve, in the vicinity of valvular macrophages (59,60). During disease, mast cells are activated and they produce cathepsin G, which causes elastin degradation in the stenotic valve (59). These cells appear to induce angiogenesis during the aortic valve stenosis process, and a positive correlation between mast cell and neovessel density has been documented in this condition. Mast cells can produce vascular endothelial growth factor (VEGF) and they are closely localized to neovessels in the stenotic valve (61). Tryptase, which is released by activated mast cells, negatively regulates levels of the endogenous angiogenesis inhibitor endostatin (61,62). Thus, these cells promote angiogenesis in aortic valve stenosis by VEGF secretion and downregulation of endostatin. In contrast, mast cells play a regulatory function in lymphangiogenesis by suppressing VEGF-C secreted by valvular myofibroblasts (63). These dual functions of mast cells indicate their versatility in regulating neovascularization in aortic valve disease.

**CONCLUSION**

Various cellular components participate in the progression of aortic valve stenosis. Damage to VECs triggers the onset of disease and upregulates cell adhesion molecules, promoting inflammatory immune cell infiltration of the aortic valve. Infiltrating inflammatory cells secrete cytokines, and induce endothelial-mesenchymal transition of VECs to VICs. These events trigger the differentiation of VICs into myofibroblasts and osteoblast-like cells, causing fibrosis and calcification. Macrophages and mast cells directly affect the disease progression and cause lipid accumulation, angiogenesis, and extracellular matrix remodeling. The adaptive immune response effected by T cells and B cells also affects the progress of this disease. In addition, DCs may participate in aortic valve stenosis by regulating T cell immunity. However, the pathogenesis of this condition remains largely unknown. Additional studies are required to understand valvular immune cell networks and their crosstalk with VICs and VECs, which will provide new therapeutic options for aortic valve stenosis.

**ACKNOWLEDGEMENTS**

This work was supported by the research fund of Hanyang University (HY-2012-N).

**CONFLICTS OF INTEREST**

The authors have no financial conflict of interest.

**REFERENCES**

1. Dweck, M. R., N. A. Boon, and D. E. Newby. 2012. Calcific aortic stenosis: a disease of the valve and the myocardium. *J. Am. Coll. Cardiol.* 60: 1854-1863.
2. Towler, D. A. 2013. Molecular and cellular aspects of calcific aortic valve disease. *Circ. Res.* 113: 198-208.
3. Nkomo, V. T., J. M. Gardin, T. N. Skelton, J. S. Gottdiener, C. G. Scott, and M. Enriquez-Sarano. 2006. Burden of valvular heart diseases: a population-based study. *Lancet* 368: 1005-1011.
The Function of Immune Cells in Aortic Valve Stenosis
Seung Hyun Lee and Jae-Hoon Choi

4. Otto, C. M., B. K. Lind, D. W. Kitzman, B. J. Gersh, and D. S. Siscovick. 1999. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N. Engl. J. Med.* 341:142-147.

5. Otto, C. M. 2000. Timing of aortic valve surgery. *Heart* 84: 211-218.

6. Moura, L. M., S. F. Ramos, J. L. Zamorano, I. M. Barros, L. F. Azevedo, F. Rocha-Goncalves, and N. M. Rajamannan. 2007. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. *J. Am. Coll. Cardiol.* 49: 554-561.

7. Rosenhek, R., F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, M. Schemper, T. Binder, G. Maurer, and H. Baumgartner. 2004. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. *Circulation* 110: 1291-1295.

8. Cowell, S. J., D. E. Newby, R. J. Prescott, P. Bloomfield, J. Reid, D. B. Northridge, and N. A. Boon. 2005. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N. Engl. J. Med.* 352: 2389-2397.

9. Rossevo, A. B., T. R. Pedersen, K. Boman, P. Brud, J. B. Chambers, K. Egstrup, E. Gerds, C. Gohlie-Barwolf, I. Holme, Y. A. Kesandani, W. Malbreg, C. A. Nienaber, S. Ray, T. Skiarme, K. Wachtell, and R. Willenheimer. 2008. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *Circulation* 116: 1343-1356.

10. Aikawa, E., and C. M. Otto. 2012. Look more closely at the valve: imaging calcific aortic valve disease. *Circulation* 125: 9-11.

11. New, S. E., and E. Aikawa. 2011. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. *Circ. Res.* 108: 1381-1391.

12. Combs, M. D., and K. E. Yutzey. 2009. Heart valve development: regulatory networks in development and disease. *Circ. Res.* 105: 408-421.

13. Wang, H., L. A. Leinwand, and K. S. Anseth. 2014. Cardiac valve cells and their microenvironment—insights from in vitro studies. *Nat. Rev. Cardiol.* 11: 715-727.

14. Liu, A. C., V. R. Joag, and A. I. Gotlieb. 2007. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. *Am. J. Pathol.* 171: 1407-1418.

15. Rajamannan, N. M., F. J. Evans, E. Aikawa, K. J. Grande-Allen, L. L. Demer, D. D. Heistad, C. A. Simmons, K. S. Masters, P. Mathieu, K. D. O'Brien, F. J. Schoen, D. A. Towler, A. P. Yoganathan, and C. M. Otto. 2011. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary. Calcific aortic valve disease-2011 update. *Circulation* 124: 1783-1791.

16. Jian, B., N. Naruda, Q. Y. Li, E. R. Mohler, III, and R. J. Levy. 2003. Progression of aortic valve stenosis: TGF-beta is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. *Ann. Thorac. Surg.* 75: 457-465.

17. Li, C., and A. I. Gotlieb. 2011. Transforming growth factor-beta regulates the growth of valve interstitial cells in vitro. *Am. J. Pathol.* 179: 1746-1755.

18. Osman, L., M. H. Yacoub, N. Latif, M. Amrani, and A. H. Chester. 2006. Role of human interstitial cells in valve calcification and their response to atorvastatin. *Circulation* 114: 1547-1552.

19. Hinz, B. 2007. Formation and function of the myofibroblast during tissue repair. *J. Invest. Dermatol.* 127: 526-537.

20. Rajamannan, N. M., M. Subramaniam, D. Rickard, S. R. Stock, J. Donovan, M. Springer, T. Orszulak, D. A. Fullerton, A. J. Tajik, R. O. Bonow, and T. Spelsberg. 2003. Human aortic valve calcification is associated with an osteoblast phenotype. *Circulation* 107: 2181-2184.

21. Yang, X., X. Meng, X. Su, D. C. Mauchley, L. Ao, J. C. Cleveland, Jr., and D. A. Fullerton. 2009. Bone morphogenetic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2. *J. Thorac. Cardiovasc. Surg.* 138: 1008-1015.

22. Alexopoulos, A., V. Bravou, S. Peroukedi, L. Kaklamanis, J. Varakis, D. Alexopoulos, and H. Papadaki. 2010. Bone regulatory factors Nfatc1 and Osterix in human calcific aortic valves. *Int. J. Cardiol.* 139: 142-149.

23. Filip, D. A., A. Nistor, A. Bulla, A. Radu, F. Lupu, and M. Simionescu. 1987. Cellular events in the development of valvular atherosclerotic lesions induced by experimental hypercholesterolemia. *Atherosclerosis* 67: 199-214.

24. Syvaranta, S., M. Anne-Kinnunen, K. Oomi, R. Oksjoki, M. Kupari, P. T. Kovanen, and S. Helkjaer-Quadhel. 2014. Potential pathological roles for oxidized low-density lipoprotein and scavenger receptors SR-AI, CD36, and LOX-1 in aortic valve stenosis. *Atherosclerosis* 235: 398-407.

25. Meng, X., L. Ao, Y. Song, A. Bahu, X. Yang, M. Wang, M. J. Weyant, C. A. Dinarello, J. C. Cleveland, Jr., and D. A. Fullerton. 2008. Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. *Am. J. Physiol. Cell Physiol.* 294: C29-C35.

26. Yang, X., D. A. Fullerton, X. Su, L. Ao, J. C. Cleveland, Jr., and X. Meng. 2009. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. *J. Am. Coll. Cardiol.* 53: 491-500.

27. Bischoff, J., and E. Aikawa. 2011. Progenitor cells confer plasticity to cardiac valve endothelium. *J. Cardiovasc. Transl. Res.* 4: 710-719.

28. Olsson, M., J. Thyberg, and J. Nilsson. 1999. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. *Arterioscler. Thromb. Vasc. Biol.* 19: 1218-1222.

29. Mohly, D., P. Pibarat, J. P. Despres, C. Cote, B. Arsenault, A. Cartier, P. Cosnay, C. Couture, and P. Mathieu. 2008. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. *Arterioscler. Thromb. Vasc. Biol.* 28: 187-193.

30. O'Brien, K. D., D. D. Reichenbach, S. M. Marcovina, J. Kassian, C. E. Alpers, and C. M. Otto. 1996. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. *Arterioscler. Thromb. Vasc. Biol.* 16: 523-532.

31. Sucosky, P., K. Balachandran, A. Elhammali, H. Jo, and A. P. Yoganathan. 2009. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-beta-dependent pathway. *Arterioscler. Thromb. Vasc. Biol.* 29: 254-260.
32. Kaden, J. J., C. E. Dempfle, R. Grobholz, H. T. Tran, R. Kilic, A. Sarikoc, M. Brueckmann, C. Vahl, S. Hagle, K. K. Haase, and M. Borggreve. 2003. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. *Atherosclerosis* 170: 205-211.

33. Weiss, R. M., J. D. Miller, and D. D. Heistad. 2013. Fibrocalcific aortic valve disease: opportunity to understand disease mechanisms using mouse models. *Circ. Res.* 113: 209-222.

34. Mahler, G. J., E. J. Farrar, and J. T. Butcher. 2013. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* 33: 121-130.

35. Guerraty, M. A., G. R. Grant, J. W. Karanian, O. A. Chiesa, W. F. Pritchard, and P. F. Davies. 2010. Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium. *Arterioscler. Thromb. Vasc. Biol.* 30: 225-231.

36. Duan, S. Z., M. G. Usher, and R. M. Mortensen. 2008. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. *Circ. Res.* 102: 283-294.

37. Jackson, S. M., F. Parhami, X. P. Xi, J. A. Berliner, W. A. Hsueh, R. E. Law, and L. L. Demer. 1999. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. *Arterioscler. Thromb. Vasc. Biol.* 19: 2094-2104.

38. Aikawa, E., M. Nahrendorf, D. Sosnovik, V. M. Lok, F. A. Jaffar, M. Aikawa, and R. Weissleder. 2007. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. *Circulation* 115: 377-386.

39. Otto, C. M., J. Kuusisto, D. D. Reichenbach, A. M. Gown, and J. L. Figueiredo, G. Rusanescu, F. Pritchard, and P. F. Davies. 2010. Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.

40. Bobryshev, Y. V. 2006. Monocyte recruitment and foam cell formation in atherosclerosis. *Crit. Rev. Eukaryot. Gene Expr.* 20: 87-103.

41. Aikawa, E., M. Aikawa, P. Libby, J. L. Figueiredo, G. Rusanescu, Y. Iwamoto, D. Fukuda, R. H. Kohler, G. P. Shi, F. A. Jaffar, and R. Weissleder. 2009. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. *Circulation* 119: 1785-1794.

42. Brown, M. S., and J. L. Goldstein. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. *Annu. Rev. Biochem.* 52: 223-261.

43. Choi, J. H., Y. Do, C. Cheong, H. Koh, S. B. Boscardin, Y. S. Oh, L. Bozzacco, C. Trumpfthaler, C. G. Park, and R. M. Steinman. 2009. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. *J. Exp. Med.* 206: 497-505.

44. Choi, J. H., C. Cheong, D. B. Dandamudi, C. G. Park, A. Rodriguez, S. Mehandru, K. Velinzon, I. H. Jung, J. Y. Yoo, G. T. Oh, and R. M. Steinman. 2011. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. *Immunity* 35: 819-831.

45. Koltseva, E. K., and K. Levy. 2011. How dendritic cells shape atherosclerosis. *Trends Immunol.* 32: 540-547.

46. Steiner, I., L. Krbl, T. Rozkos, J. Harrer, and J. Laco. 2012. Calcific aortic valve stenosis: Immunohistochemical analysis of inflammatory infiltrate. *Pathol. Res. Pract.* 208: 231-234.

47. Wu, H. D., M. S. Maurer, R. A. Friedman, C. C. Marbore, E. M. Ruiz-Vazquez, R. Ramakrishnan, A. Schwartz, M. D. Tilson, A. S. Stewart, and R. Winchester. 2007. The lymphoedinfiltration in calcific aortic valve stenosis predominantly consists of clonally expanded T cells. *J. Immunol.* 178: 5329-5339.

48. Winchester, R., M. Wiesendanger, W. O’Brien, H. Z. Zhang, M. S. Maurer, L. D. Gillam, A. Schwartz, C. Marbore, and A. S. Stewart. 2011. Circulating activated and effector memory T cells are associated with calcification and clonal expansions in bicuspid and tricuspid valves of calcific aortic stenosis. *J. Immunol.* 187: 1006-1014.

49. Natorska, J., G. Marek, J. Sadowski, and A. Undas. 2016. Presence of B cells within aortic valves in patients with aortic stenosis: Relation to severity of the disease. *J. Cardiol.* 67: 80-85.

50. Helske, S., M. Kupari, J. Lappalainen, M. Laine, S. Stewart, S. S. Stewart, and R. Winchester. 2007. The lymphoedinfiltration in calcific aortic valve stenosis predominantly consists of clonally expanded T cells. *Circulation* 118: 10-24.

51. Mackay, F., and J. L. Browning. 2002. BAFF: a fundamental survival factor for B cells. *Nat. Rev. Immunol.* 2: 465-475.

52. Mackay, F., P. Schneider, P. Rennert, and J. Browning. 2003. BAFF AND APRIL: a tutorial on B cell survival. *Nat. Rev. Immunol.* 3: 540-547.

53. Nardelli, B., O. Belvedere, V. Roschke, S. Sosnovtseva, J. A. Carrell, P. Feng, J. G. Giri, T. S. Migone, S. Sosnovtseva, J. A. Carrell, P. Feng, J. G. Giri, and D. M. Hilbert. 2001. Synthesis and release of B-lymphocyte activating factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. *Int. J. Mol. Med.* 16: 869-872.

54. Khan, R., and R. Sheppard. 2006. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. *Immunology* 118: 10-24.

55. Parameswaran, N., and S. Patial. 2010. Tumor necrosis factor-alpha signaling in macrophages. *Crit. Rev. Eukaryot. Gene Expr.* 20: 87-103.

56. Brown, M. S., and J. L. Goldstein. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. *Annu. Rev. Biochem.* 52: 223-261.
61. Syvaranta, S., S. Helske, M. Laine, J. Lappalainen, M. Kupari, M. I. Mayranpaa, K. A. Lindstedt, and P. T. Kovanen. 2010. Vascular endothelial growth factor-secreting mast cells and myofibroblasts: a novel self-perpetuating angiogenic pathway in aortic valve stenosis. *Arterioscler. Thromb. Vasc. Biol.* 30: 1220-1227.

62. O'Reilly, M. S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen, and J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 88: 277-285.

63. Syvaranta, S., S. Helske, J. Lappalainen, M. Kupari, and P. T. Kovanen. 2012. Lymphangiogenesis in aortic valve stenosis–novel regulatory roles for valvular myofibroblasts and mast cells. *Atherosclerosis* 221: 366-374.